News & Events

2015 Year in Review and 2016 Outlook

by Insight Genetics
January 20, 2016

2015 was an exciting year for Insight Genetics with the formation of new partnerships, continued collaboration with existing partners, expansion of our leadership team, the launch of a CLIA-validated assay for non-small cell lung cancer (NSCLC), presentation of new research findings on triple negative breast cancer (TNBC), and new funding to continue the advancement of the company’s TNBC and NSCLC programs.   We look forward to an eventful 2016 as we continue to clinically validate and commercialize our breast and lung cancer assays, adapt these assays for compatibility with liquid biopsies and broader, multi-biomarker panels, expand collaborations with key academic institutions and commercial partners, and extend our services to the pharmaceutical industry. 

Insight ALK Screen Technology Clinically Validated

by Insight Genetics
December 30, 2015

The Archives of Pathology and Laboratory Medicine recently published an article by a group from the Department of Pathology and Genomic Medicine at Houston Methodist Hospital who performed a clinical validation of the Insight ALK Screen qPCR assay which is manufactured and distributed globally by QIAGEN as ALK RGQ RT-PCR Kit.

Ronald A. Andrews Joins Insight Genetics’ Board of Directors, Leads Capital Raise

by Insight Genetics
November 10, 2015

Insight Genetics, Inc. today announced that Ronald (Ronnie) Andrews Jr., former president of the Genetic Science Division of Thermo Fisher Scientific, has been named to the company’s Board of Directors. Andrews also joined the company’s base of private investors, in a round of $3 Million growth capital that will allow Insight Genetics to expand and expedite its triple negative breast cancer and non-small cell lung cancer programs.  The minimum of $3 million has been closed, with a maximum of $5 million targeted.

Insight Genetics at AMP Annual Meeting

by Insight Genetics
October 30, 2015

Insight Genetics will attend the Association for Molecular Pathology (AMP) 2015 Annual Meeting in Austin, Texas from November 4-7, 2015.   At the event, Insight Genetics will be available to discuss its current programs focused on enabling precision medicine in non-small cell lung cancer and triple-negative breast cancer as well as its service offerings including custom assay design and development and specialized pharmaceutical services.

Page 2 of 15 (73 items)

|< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 >|